UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

P448: PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA

HemaSphere, 2022-06, Vol.6, p.348-349

2022

Volltextzugriff (PDF)

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia

Leukemia, 2018-01, Vol.32 (1), p.30-37

2018

Volltextzugriff (PDF)

S1616 MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA (AML) WITH T(8;21)(Q22;Q22.1); RUNX1‐RUNX1T1: RESULTS OF THE AML STUDY GROUP (AMLSG)

HemaSphere, 2019-06, Vol.3 (S1), p.745-746

2019

Volltextzugriff (PDF)

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial

The Lancet. Haematology, 2023-07, Vol.10 (7), p.e495-e509

2023

Volltextzugriff (PDF)

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

Nature communications, 2019-05, Vol.10 (1), p.2031-2031, Article 2031

2019

Volltextzugriff (PDF)

ClimateNet: an expert-labeled open dataset and deep learning architecture for enabling high-precision analyses of extreme weather

Geoscientific Model Development, 2021-01, Vol.14 (1), p.107-124

2021

Volltextzugriff (PDF)

Using Deep Learning for an Analysis of Atmospheric Rivers in a High‐Resolution Large Ensemble Climate Data Set

Journal of advances in modeling earth systems, 2023-04, Vol.15 (4), p.n/a

2023

Volltextzugriff (PDF)

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

Journal of hematology and oncology, 2023-08, Vol.16 (1), p.1-96, Article 96

2023

Volltextzugriff (PDF)

18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting

Pathogens (Basel), 2022-03, Vol.11 (3), p.348

2022

Volltextzugriff (PDF)

Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature

Expert opinion on pharmacotherapy, 2022-03, Vol.23 (5), p.561-571

2022

Volltextzugriff (PDF)

A novel thick photoresist for microsystem technology

Microelectronic engineering, 2003-06, Vol.67, p.259-265

2003

Volltextzugriff (PDF)

Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia

Blood, 2013-07, Vol.122 (1), p.100-108

2013

Volltextzugriff (PDF)

TP53 abnormalities and chromosomal aneuploidy in acute panmyelosis with myelofibrosis

Leukemia, 2019-12, Vol.33 (12), p.2956-2962

2019

Volltextzugriff (PDF)

Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1 m Patients Achieving MRD-Negative CR after Intensive Induction

Blood, 2022-11, Vol.140 (Supplement 1), p.6293-6294

2022

Volltextzugriff (PDF)

SISA: Set-Centric Instruction Set Architecture for Graph Mining on Processing-in-Memory Systems

MICRO-54: 54th Annual IEEE/ACM International Symposium on Microarchitecture, 2021, p.282-297

2021

Volltextzugriff (PDF)

First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease

Blood, 2020-11, Vol.136 (Supplement 1), p.8-9

2020

Volltextzugriff (PDF)

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Blood, 2021-11, Vol.138 (Supplement 1), p.3410-3410

2021

Volltextzugriff (PDF)

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood, 2022-11, Vol.140 (Supplement 1), p.145-149

2022

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(47)
Tagungsberichte
(1)

Sprache

Englisch
(38)
Deutsch
(10)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Humans
(16)
Life Sciences & Biomedicine
(12)
Female
(10)
Adult
(8)
Male
(8)
Middle Aged
(8)
Hematology
(7)
Aged
(6)
Leukemia, Myeloid, Acute - Genetics
(6)
Mutation
(5)
Nuclear Proteins - Genetics
(5)
Young Adult
(5)
Leukemia, Myeloid, Acute - Diagnosis
(4)
Oncology
(4)
Patients
(4)
Adolescent
(3)
Diagnosis, Differential
(3)
Leukemia
(3)
Leukemia, Myeloid, Acute - Drug Therapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(20)
Hemasphere
(4)
Leukemia
(2)
Pathogens
(2)
Radiologe
(2)
Strahlentherapie
(2)
Archives Of Gynecology
(1)
Arzneimittel-Forschung
(1)
Deutsche Zeitschrift Für Nervenheilkunde
(1)
Expert Opinion On Pharmacotherapy
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

P448: PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA

P548: BEMCENTINIB COMBINED WITH LOW‐DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408)

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia

S1616 MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA (AML) WITH T(8;21)(Q22;Q22.1); RUNX1‐RUNX1T1: RESULTS OF THE AML STUDY GROUP (AMLSG)

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

Gemtuzumab Ozogamicin in NPM1 -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study

ClimateNet: an expert-labeled open dataset and deep learning architecture for enabling high-precision analyses of extreme weather

Using Deep Learning for an Analysis of Atmospheric Rivers in a High‐Resolution Large Ensemble Climate Data Set

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

S135: NEXT‐GENERATION SEQUENCING‐BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN

18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting

Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

A novel thick photoresist for microsystem technology

Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia

TP53 abnormalities and chromosomal aneuploidy in acute panmyelosis with myelofibrosis

Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction

Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1 m Patients Achieving MRD-Negative CR after Intensive Induction

SISA: Set-Centric Instruction Set Architecture for Graph Mining on Processing-in-Memory Systems

First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Suchergebnisse filtern